

## Product Information

**Product ID** D364086

**CAS No.** 944842-54-0

**Chemical Name**

**Synonym** VX-509, VRT-831509, Adelitinib

**Formula** C<sub>18</sub>H<sub>19</sub>F<sub>3</sub>N<sub>6</sub>O

**Formula Wt.** 392.39

**Melting Point**


**Purity** ≥98%

**Solubility**

**Store Temp** -20° C

**Ship Temp** Ambient

**Description** Decernotinib is a potent and selective inhibitor of JAK3. It exhibits anti-inflammatory effects in rat models of rheumatoid arthritis, while avoiding hematopoiesis, a problem with current non-selective JAK inhibitors. Methotrexate treatment is also improved when used in combination with decernotinib.



<b>Product ID</b>	<b>Size</b>
D364086	1 mg
D364086	5 mg
D364086	25 mg
D364086	100 mg

**References** Farmer L., Ledebor M., et al. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases. *J Med Chem.* 58(18):7195-216 (2015). PMID: 26230873.

Elwood F., Witter D., et al. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor. *361(2):229-44* (2017). PMID:28193636.

Genovese M., van Vollenhoven R., et al. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. *Arthritis Rheumatol.* 68(1):46-55 (2016). PMID: 26473751.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.